90 related articles for article (PubMed ID: 24996060)
21. SUMO: the glue that binds.
Matunis MJ; Zhang XD; Ellis NA
Dev Cell; 2006 Nov; 11(5):596-7. PubMed ID: 17084352
[TBL] [Abstract][Full Text] [Related]
22. MPSR1 is a cytoplasmic PQC E3 ligase for eliminating emergent misfolded proteins in
Kim JH; Cho SK; Oh TR; Ryu MY; Yang SW; Kim WT
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):E10009-E10017. PubMed ID: 29087340
[TBL] [Abstract][Full Text] [Related]
23. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus.
Müller S; Matunis MJ; Dejean A
EMBO J; 1998 Jan; 17(1):61-70. PubMed ID: 9427741
[TBL] [Abstract][Full Text] [Related]
24. SUMO5, a Novel Poly-SUMO Isoform, Regulates PML Nuclear Bodies.
Liang YC; Lee CC; Yao YL; Lai CC; Schmitz ML; Yang WM
Sci Rep; 2016 May; 6():26509. PubMed ID: 27211601
[TBL] [Abstract][Full Text] [Related]
25. The Molecular Interface Between the SUMO and Ubiquitin Systems.
Staudinger JL
Adv Exp Med Biol; 2017; 963():99-110. PubMed ID: 28197908
[TBL] [Abstract][Full Text] [Related]
26. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
27. Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
[TBL] [Abstract][Full Text] [Related]
28. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.
Xu Y; Ahn JH; Cheng M; apRhys CM; Chiou CJ; Zong J; Matunis MJ; Hayward GS
J Virol; 2001 Nov; 75(22):10683-95. PubMed ID: 11602710
[TBL] [Abstract][Full Text] [Related]
29. Molecular chaperones in targeting misfolded proteins for ubiquitin-dependent degradation.
Kriegenburg F; Ellgaard L; Hartmann-Petersen R
FEBS J; 2012 Feb; 279(4):532-42. PubMed ID: 22177318
[TBL] [Abstract][Full Text] [Related]
30. Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein.
Fu L; Gao YS; Sztul E
Neurobiol Dis; 2005 Dec; 20(3):656-65. PubMed ID: 15964198
[TBL] [Abstract][Full Text] [Related]
31. Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a mechanism for SUMO paralog selection.
Tatham MH; Kim S; Jaffray E; Song J; Chen Y; Hay RT
Nat Struct Mol Biol; 2005 Jan; 12(1):67-74. PubMed ID: 15608651
[TBL] [Abstract][Full Text] [Related]
32. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
Kunapuli P; Kasyapa CS; Chin SF; Caldas C; Cowell JK
Exp Cell Res; 2006 Nov; 312(19):3739-51. PubMed ID: 17027752
[TBL] [Abstract][Full Text] [Related]
33. Stabilization of nuclear oncoproteins by RNF4 and the ubiquitin system in cancer.
Diefenbacher M; Orian A
Mol Cell Oncol; 2017; 4(1):e1260671. PubMed ID: 28197534
[TBL] [Abstract][Full Text] [Related]
34. Try Me: Promiscuous Inhibitors Still Allow for Selective Targeted Protein Degradation.
Müller MP; Rauh D
Cell Chem Biol; 2018 Jan; 25(1):4-6. PubMed ID: 29351837
[TBL] [Abstract][Full Text] [Related]
35. Uncovering global SUMOylation signaling networks in a site-specific manner.
Hendriks IA; D'Souza RC; Yang B; Verlaan-de Vries M; Mann M; Vertegaal AC
Nat Struct Mol Biol; 2014 Oct; 21(10):927-36. PubMed ID: 25218447
[TBL] [Abstract][Full Text] [Related]
36. PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation.
Sahin U; de Thé H; Lallemand-Breitenbach V
Nucleus; 2014; 5(6):499-507. PubMed ID: 25482067
[TBL] [Abstract][Full Text] [Related]
37. Ubiquitin-SUMO circuitry controls activated fanconi anemia ID complex dosage in response to DNA damage.
Gibbs-Seymour I; Oka Y; Rajendra E; Weinert BT; Passmore LA; Patel KJ; Olsen JV; Choudhary C; Bekker-Jensen S; Mailand N
Mol Cell; 2015 Jan; 57(1):150-64. PubMed ID: 25557546
[TBL] [Abstract][Full Text] [Related]
38. ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation.
Dassouki Z; Sahin U; El Hajj H; Jollivet F; Kfoury Y; Lallemand-Breitenbach V; Hermine O; de Thé H; Bazarbachi A
Blood; 2015 Jan; 125(3):474-82. PubMed ID: 25395419
[TBL] [Abstract][Full Text] [Related]
39. RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway.
Xie J; Kim H; Moreau LA; Puhalla S; Garber J; Al Abo M; Takeda S; D'Andrea AD
J Clin Invest; 2015 Apr; 125(4):1523-32. PubMed ID: 25751062
[TBL] [Abstract][Full Text] [Related]
40. PML nuclear bodies: regulation, function and therapeutic perspectives.
Sahin U; Lallemand-Breitenbach V; de Thé H
J Pathol; 2014 Nov; 234(3):289-91. PubMed ID: 25138686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
